Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
May 13, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in...
Collegium Announces $35 Million Accelerated Share Repurchase Program
May 13, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
May 13, 2024 08:00 ET
|
Annexon Biosciences
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the...
Pan American Energy Commences the Spring 2024 Field Prospecting and Sampling Program At The Big Mack Lithium Project
May 13, 2024 08:00 ET
|
Pan American Energy Corp.
CALGARY, Alberta, May 13, 2024 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTCQB: PAANF | FRA: SS60) ("Pan American” or the "Company") is pleased to announce the commencement of the...
Genius Group Schedules Full Year 2023 Earnings Call Thursday, May 16, 2024 at 8:30am ET
May 13, 2024 08:00 ET
|
Genius Group Limited
Singapore, May 13, 2024 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) ("Genius Group" or the "Company"), a leading provider of AI-powered, digital-first education solutions, will...
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
May 13, 2024 08:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024 08:00 ET
|
Imunon, Inc.
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on...
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
May 13, 2024 08:00 ET
|
Recce Pharmaceuticals
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327 is being evaluated for potential use to...